Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer.
Authors: Wang C, Zhu M, Bao L, Toffessi Tcheuyap V, Brugarolas J, Luo W, Wang Y
Journal: Journal of experimental & clinical cancer research : CR
group therapy
mental health
open access